"BIIB – Biogen Manufacturing Campus – Solothurn - Project Profile" contains information on the scope of the project including project overview and location. The profile also details project ownership and funding, gives a full project description, as well as information on contracts, tendering and key project contacts.
The "BIIB – Biogen Manufacturing Campus – Solothurn - Project Profile" is part of Timetric's database of 82,000+ construction projects. Our database includes a 10+ year archive of completed projects, full coverage of all global projects with a value greater than $25 million and key contact details for project managers, owners, consultants, contractors and bidders.
Biogen Switzerland AG (BIIB) is undertaking the development of Biogen manufacturing campus with seven buildings on a 20.4ha area in Luterbach Solothurn Canton, Switzerland.
The project involves the construction of a five-story 39.33m high production building with gross floor area of 34,940m2, a 29.48m high storage building, a four-story administrative building with an auditorium with seating capacity of 320 persons, a mezzanine with 85 seats, office facilities with gross floor area of 1,185m2, data center, training center, a teleconferencing facility with 979m2, a lounge for 150 people, a preparation kitchen, seating area and coffee bar, a central plant building with boiler rooms, office facilities, workshops, first aid facility, construction of laboratories, supply buildings, a catering building, and the installation of air compressors, power transmission and radiator wings, two manufacturing cells containing four 15,000 liters bioreactors each, mass production cells, a multistory parking facility for 1,200 vehicles.
The project is being built in two phases.
The administrative building is being built in two phases.
On July 1, 2015, Biogen signed a preliminary contract with the canton of Solothurn to build a manufacturing plant.
Q3 2015, a design and planning contract was awarded to Burckhardt+Partner AG.
On January 5, 2016, Jacobs Engineering Group has been appointed as engineering, procurement and construction management (EPCM) contract.
Marti Generalunternehmung AG and Implenia AG has been appointed as sub-contractor for the central plant building.
On January 29, 2016, the construction work was commenced and scheduled for completion in the fourth quarter of 2018.
On March 14, 2016, Marti Generalunternehmung AG commenced the construction of a central plant building and completed by 2016.
Construction works are underway.
The project involves the construction of a drugs manufacturing plant on a 20ha area in Luterbach Solothurn Canton, Switzerland.
The US$1,063 million project includes the following:
1. Construction of a five-story 39.33m high production building with gross floor area of 34,940m2
2. Construction of a 29.48m high storage building
3. Construction of a four-story administrative building with an auditorium with seating capacity of 320 persons
4. Construction of a central plant building with boiler rooms
5. Construction of a multistory parking facility for 1,200 vehicles
6. Installation of air compressors
7. Installation of power transmission
8. Installation of radiator wings
9. Installation of two manufacturing cells containing four 15,000 liters bioreactors each
10. Installation of mass production cellsReasons To Buy